Journal
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 24, Issue 4, Pages 471-475Publisher
INFORMA HEALTHCARE
DOI: 10.1517/13543776.2014.865725
Keywords
aerosol; asthma; chronic obstructive pulmonary disease; GSK-2269557; phosphatidylinositol 3-kinase-delta inhibitor; RV-1729
Categories
Ask authors/readers for more resources
This application claims two crystalline forms and inhaled formulations of a the selective phosphatidylinositol 3-kinase-delta inhibitor (PI3K delta) inhibitor 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl) hex-5-ynamide. These formulations are claimed to be useful in the treatment of respiratory diseases including asthma and chronic obstructive pulmonary disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available